Physician profile
Clinton Ogolo
NPI 1730219981
$3,901.59
in general payments reported to CMS, 2019-2025
21 companies · $590 in 2025
The $590 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $738 · 2020: $343 · 2021: $453 · 2022: $505 · 2023: $678 · 2024: $595 · 2025: $590.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,863.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,862.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $964.59 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $410.65 | 2019-2025 | Jardiance, Tradjenta |
| Novartis Pharmaceuticals Corporation | $409.34 | 2019-2022 | |
| Glaxosmithkline, LLC. | $288.28 | 2021-2025 | Trelegy Ellipta |
| Novo Nordisk INC | $261.07 | 2019-2024 | Rybelsus, Ozempic |
| Lilly USA, LLC | $248.14 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Sumitomo Pharma America, INC. | $239.72 | 2023-2025 | Gemtesa |
| Pfizer INC. | $164.25 | 2020-2022 | |
| Amarin Pharma, INC. | $138.46 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $112.15 | 2019-2023 | Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $110.81 | 2022-2024 | |
| Exact Sciences Corporation | $93.32 | 2023-2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $84.63 | 2019-2023 | |
| Abbott Laboratories | $79.80 | 2021-2024 | Freestyle Libre 3 |
| Sunovion Pharmaceuticals INC. | $76.91 | 2021-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $69.41 | 2019-2023 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $52.62 | 2019-2022 | |
| Amgen INC. | $31.98 | 2023-2024 | Otezla, Repatha |
| Avanir Pharmaceuticals, INC. | $26.69 | 2019-2021 | |
| Inspire Medical Systems, INC. | $25.62 | 2024 | Inspire |
| Philips North America LLC | $13.15 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clinton Ogolo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.